The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksArcontech Group Regulatory News (ARC)

Share Price Information for Arcontech Group (ARC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 103.50
Bid: 102.00
Ask: 105.00
Change: 0.00 (0.00%)
Spread: 3.00 (2.941%)
Open: 103.50
High: 103.50
Low: 103.50
Prev. Close: 103.50
ARC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

27 Sep 2017 17:23

RNS Number : 0198S
Arcontech Group PLC
27 September 2017
 

 

AorTech International plc

("AorTech"or the "Company")

 

Result of AGM

 

 

AorTech International plc (AIM: AOR), the biomaterials and medical device IP company, is pleased to announce that at the Annual General Meeting held today, all the resolutions were duly passed.

 

 

For further information contact:

 

AorTech International plc 

Eddie McDaid, Chief Executive Tel: +44 (0)7802 920869

 

AorTech International plc 

Bill Brown, Chairman Tel: +44 (0)7730 718296 

 

finnCap Limited

Jonny Franklin-Adams / Giles Rolls Tel: +44 20 7220 0500 

 

 

 

 

About AorTech:

 

AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

 

Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGOKODBABKDBCB
Date   Source Headline
16th Nov 200510:23 amRNSHolding(s) in Company
12th Oct 20057:00 amRNSFinal Results
23rd Aug 20053:10 pmRNSHolding(s) in Company
30th Jun 20052:51 pmRNSDirectorate Change
16th May 200512:48 pmRNSHolding(s) in Company
10th May 200512:04 pmRNSDirector Shareholding
7th Apr 20052:33 pmRNSHolding(s) in Company
4th Apr 20057:00 amRNSProduct Launch
23rd Mar 20057:00 amRNSInterim Results
27th Jan 20054:59 pmRNSHolding(s) in Company
18th Jan 20054:37 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.